CCL2 and Patent ductus arteriosus: We showed that the bispecific fusion protein 17V05 effectively inhibited multiple proinflammatory cytokines and chemokines, including IL-6, IL-8, CXCL1, and MCP-1, and thus may be effective in treating immune-induced PDA.